Kailera Therapeutics (KLRA) news

Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra sells 34.2 mln shares in Korra Holding for EGP 205.3 mln - EGX

Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra has sold 34.2 million shares in Korra Holding (KORA) for a total value of EGP 205.3 million, according to recent data from the Egyptian Exchange . The transaction reflects significant activity in the stock, which has seen a recent decline in…

Kailera Therapeutics - Topline data from Kainetic phase 3 trials expected in mid-2028

Novo says Hengrui obesity pill to enter phase 1 tests soon

Kailera Therapeutics, in collaboration with Chinese pharmaceutical firm Hengrui Medicine, has announced the initiation of phase 1 trials for a novel triple-receptor obesity compound targeting GLP-1, GIP, and glucagon receptors. This development positions the drug as a potential competitor in the…

Jiangsu Hengrui Pharmaceuticals says unit's ribupatide injection marketing application accepted by China's drug regulator

Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for ribupatide injection for the treatment of type 2 diabetes. This follows the successful completion of a Phase 3 clinical trial…

Shares of Kailera Therapeutics up 1% after weight-loss drug meets main goal of late-stage trials in China

Shares of Kailera Therapeutics (Nasdaq: KLRA) rose 1% following the announcement that its weight-loss drug, HRS-9531 (KAI-9531), met its primary endpoints in a late-stage clinical trial conducted in China. The Phase 3 GEMINI-1 trial, led by partner Hengrui Pharma, demonstrated significant weight…